Back to Directory
Last Updated: 05/06/2026
Draig Therapeutics
Cardiff
Founded 2021
Small molecule neuromodulators for neuropsychiatric disorders
Draig Therapeutics is a clinical-stage biotech developing small molecule drugs that modulate the glutamate and GABA neurotransmitter pathways to treat neuropsychiatric disorders.
Its lead candidate DT-101 is an AMPA receptor positive allosteric modulator in Phase 2 development for major depressive disorder. The pipeline also includes selective GABAA receptor modulators advancing towards clinical development.
Draig's science is founded on research from the Medicines Discovery Institute at Cardiff University.